Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jiangsu Bioperfectus Technologies Co (SHSE:688399) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Jiangsu Bioperfectus Technologies Co had a gross margin of 68.86% for the quarter that ended in Jun. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Jiangsu Bioperfectus Technologies Co Gross Margin % Related Terms
Jiangsu Bioperfectus Technologies Co Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jiangsu Bioperfectus Technologies Co Gross Margin % Chart
SHSE:688399 vs VRTX, REGN, MRNA: Gross Margin % Comparison
For the Biotechnology subindustry, Jiangsu Bioperfectus Technologies Co's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jiangsu Bioperfectus Technologies Co Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Jiangsu Bioperfectus Technologies Co's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Jiangsu Bioperfectus Technologies Co's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Jiangsu Bioperfectus Technologies Co (SHSE:688399) has a Gross Margin % of 68.86% as of Jun. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Jiangsu Bioperfectus Technologies Co and its competitors. This is near median its historical median of 73.36. Over the past decade, Jiangsu Bioperfectus Technologies Co's Gross Margin % has ranged from 60.62 to 82.67. According to the industry distribution chart, Jiangsu Bioperfectus Technologies Co ranks #349 out of 737 companies in the Biotechnology industry, placing it in the top 47.4%.
Is Jiangsu Bioperfectus Technologies Co's Gross Margin % too high?
Jiangsu Bioperfectus Technologies Co's current Gross Margin % of 68.86% is near median its 10-year median of 73.36. Over the past 10 years, this metric has ranged from a low of 60.62 to a high of 82.67. The Biotechnology industry median Gross Margin % is 60.91. Jiangsu Bioperfectus Technologies Co's value of 68.86% is 13.1% above this industry median. Based on the distribution chart, Jiangsu Bioperfectus Technologies Co ranks #349 out of 737 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Jiangsu Bioperfectus Technologies Co has a GF Score™ of 61/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Jiangsu Bioperfectus Technologies Co's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Jiangsu Bioperfectus Technologies Co ranks #349 out of 737 companies for Gross Margin %. This puts Jiangsu Bioperfectus Technologies Co in the upper half of its industry. The industry median Gross Margin % is 60.91. Jiangsu Bioperfectus Technologies Co's value of 68.86% is 13.1% above this benchmark. Historically, Jiangsu Bioperfectus Technologies Co's own Gross Margin % has ranged from 60.62 to 82.67 over the past decade. While the company's 10-year median is 73.36 vs. the industry median of 60.91, Jiangsu Bioperfectus Technologies Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 737 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jiangsu Bioperfectus Technologies Co's current Gross Margin % of 68.86% is 13.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Jiangsu Bioperfectus Technologies Co and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jiangsu Bioperfectus Technologies Co's current Gross Margin % is 68.86%, which is near median its own 10-year median of 73.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangsu Bioperfectus Technologies Co stock overvalued right now?
Based on GuruFocus' analysis, Jiangsu Bioperfectus Technologies Co (SHSE:688399) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥31.15, compared to a current price of ¥26.87 — trading 13.7% below its estimated fair value. The current Gross Margin % is 68.86%, which is near median its 10-year median of 73.36 and 13.1% above the Biotechnology industry median of 60.91. Jiangsu Bioperfectus Technologies Co's overall GF Score™ is 61/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Jiangsu Bioperfectus Technologies Co (SHSE:688399), the current Gross Margin % is 68.86% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jiangsu Bioperfectus Technologies Co (SHSE:688399) Overvalued in 2026?
Based on GuruFocus' analysis, Jiangsu Bioperfectus Technologies Co stock appears to be undervalued.
The current stock price of ¥26.87 is trading 13.7% below its estimated GF Value™ of ¥31.15.
GuruFocus considers Jiangsu Bioperfectus Technologies Co to be Modestly Undervalued.
Key valuation signals for SHSE:688399:
Gross Margin %: 68.86% (near median its 10-year median of 73.36)
GF Value™: ¥31.15 vs. price of ¥26.87 (13.7% below fair value)
Industry Position: 13.1% above the Biotechnology median (#349 of 737)
No single metric tells the full story. See the SHSE:688399 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jiangsu Bioperfectus Technologies Co Ltd is engaged in product development, production and sales of disease prevention and control, female genital micro-ecological testing and tumor screening. Its products portfolio includes Fever respiratory pathogen detection series, Fever with a rash pathogen test series, Fever with bleeding pathogen test series, Foodborne diseases and diarrheal pathogen detection and Other types of pathogen detection series.
61GF Score
Get the complete analysis for SHSE:688399
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688399 has been successfully added to your 
